Ethics declarations Ethics approval All experimental procedures were performed in accordance with international guidelines for the care and use of laboratory animals, including the ARRIVE guidelines, and were consistent with national regulations
Effect of Semaglutide in Patients with the Clinically Significant Weight Regain (WR) There were no significant differences in age, sex, or baseline comorbidities between WR and non-WR groups
NCHS Data Brief (2010) (51):18
The population in SELECT was different that STEP-1 and SUMOUNT 1, with 90.1% of patients on lipid-lowering therapy and a much lower baseline LDL-C of 78 mg/dL compared to 111 mg/dL and 110 mg/dL in STEP-1 and SURMOUNT 1 respectively [33, 35, 48]
FDA-approved drugs and clinical trials Lipid metabolism is central to various diseases, such as dyslipidemia, atherosclerosis, MS, osteoporosis, obesity, and NAFLD
Coverage is increasing but not universal